Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

PET imaging in multiple sclerosis (2014)

  • Authors:
  • USP affiliated authors: BUCHPIGUEL, CARLOS ALBERTO - FM
  • USP Schools: FM
  • DOI: 10.1007/s11481-014-9544-2
  • Subjects: ESCLEROSE MÚLTIPLA; TOMOGRAFIA COMPUTADORIZADA POR EMISSÃO DE PÓSITRON; DEGENERAÇÃO NEURAL
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s11481-014-9544-2 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Journal of NeuroImmune Pharmacology

    ISSN: 1557-1890

    Citescore - 2017: 3.41

    SJR - 2017: 1.379

    SNIP - 2017: 0.825


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2505343-10BCSEP 396 2014
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FARIA, Daniele de Paula; COPRAY, Sjef; BUCHPIGUEL, Carlos Alberto; DIERCKX, Rudi; VRIES, Erik de. PET imaging in multiple sclerosis. Journal of Neuroimmune Pharmacology, New York, v. 9, p. 468-482, 2014. DOI: 10.1007/s11481-014-9544-2.
    • APA

      Faria, D. de P., Copray, S., Buchpiguel, C. A., Dierckx, R., & Vries, E. de. (2014). PET imaging in multiple sclerosis. Journal of Neuroimmune Pharmacology, 9, 468-482. doi:10.1007/s11481-014-9544-2
    • NLM

      Faria D de P, Copray S, Buchpiguel CA, Dierckx R, Vries E de. PET imaging in multiple sclerosis. Journal of Neuroimmune Pharmacology. 2014 ; 9 468-482.
    • Vancouver

      Faria D de P, Copray S, Buchpiguel CA, Dierckx R, Vries E de. PET imaging in multiple sclerosis. Journal of Neuroimmune Pharmacology. 2014 ; 9 468-482.

    Referências citadas na obra
    Abourbeh G, Thézé B, Maroy R, Dubois A, Brulon V, Fontyn Y, Dollé F, Tavitian B, Boisgard R (2012) Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18 F] DTPA-714. J Neurosci 32:5728–5736
    Ahmed I, Sk B, Pavese N, Ramlackhansing A, Turheimer F, Hotton G, Hammers A, Brooks DJ (2011) Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain 134:979–986
    Bajramovic JJ, Plomp AC, Goes A et al (2000) Presentation to T cells of alpha b-crystallin in ms lesions, an early event following inflammatory demyelination. J Immunol 164:4359–4366
    Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR (1998) High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 8:228–34
    Banati RB, Newcombe J, Gunn RN et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt 11):2321–2337
    Berding G, Schneider U, Gielow P, Buchert R, Donnerstag F, Brandau W, Knapp WH, Emrich HM, Müller-Vahl K (2006). Feasibility of central cannabinoid CB1 receptor imaging with [124I] AM281 PET demonstrated in a schizophrenic patient Psychiatry Res; 147:249–256.
    Blinkenberg M, Rune K, Jønsson A, Holm S, Jensen CV, Paulson OB et al (1996) Cerebral metabolism in a case of multiple sclerosis with acute mental disorder. Acta Neurol Scand 94:310–313
    Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sorensen OS (1999) A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 53:149–53
    Bolcaen J, Acou M, Mertens K, Hallaert G, Van den Broecke C, Achten E, Goethals I (2013) Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study. J Neuroimaging 23:431–436
    Brück W (2005) Clinical implications of neuropathological findings in multiple sclerosis. J Neurol 252:10–14
    Buck D, Förschler A, Lapa C, Schuster T, Vollmar P, Korn T, Nessler S, Stadelmann C, Drzezga A, Buck AK, Wester HJ, Zimmer C, Krause BJ, Hemmer B (2012) 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. J Nucl Med 53:1269–76
    Burns HD, Van Laere K, Sanabria-Bohórquez S (2007) [18F] MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci 104(23):9800–9805
    Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW (2006) The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demeylination disease:implications for multiple sclerosis. J Neuroimmunol 174:21–31
    Carlson NG, Rojas MA, Redd JW, Tang P, Wood B, Hill KE, Rose JW (2010) Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J Neuroinflammation 7:25
    Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, Enning F, Koethe D, Leweke FM, Van Laere K (2013) Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79:304–312
    Chen SJ, Wnag YL, Fan HC, Lo WT, Wang CC, Sytwu HK (2012) Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012:970789
    Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517
    Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Preg in Multiple Sclerosis Group N Engl J Med 339:285–291
    de Paula F, De Vries EF, Sijbesma JW, Dierckx RA, Buchpiguel CA, Copray S (2014a) PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C] CIC and [11C] MeDAS. Neuroimage 87:395–402
    de Paula Faria D, Copray S, Sijbesma JW, Willemsen AT, Buchpiguel CA, Dierckx RA, de Vries EF (2014b). PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C] MeDAS, [11C] CIC and [11C] PIB. Eur J Nucl Med Mol Imaging; Feb 6. [Epub ahead of print].
    de Vries EFJ, van Waarde A, Buursma AR, Vaalburg W (2003) Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med 44(10):1700–1706
    de Vries EFJ, Doorduin J, Dierckx RAJO, van Waarde A (2008a) Evaluation of [(11) C] rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol 35(1):35–42
    de Vries EF, Doorduin J, Vellinga NA, van Waarde A, Dierckx RA, Klein HC (2008b) Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study Nucl Med Biol 35:459–66
    Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, Dierckx RA, Korf J, De Reuck JL (2003) PET visualization of microglia in multiple sclerosis patients using [11C] PK11195. Eur J Neurol 10:257–64
    Derfuss T (2012) Personalized medicine in multiple sclerosis: hope or reality? BMC Medicine 10:116
    Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50:974–81
    Doorduin J, de Vries EFJ, Dierckx RA, Klein HC (2008) PET imaging of the peripheral benzodiazepine receptor: monitoring disease progress and therapy in neurodegenerative disorders. Curr Pharm Des 14:3297–3315
    Evens N, Muccioli GG, Houbrechts N, Lambert DM, Verbruggen AM, Van Laere K, Bormans GM (2009) Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl Med Biol 36(4):455–465
    Fillippi M, Rocca MA (2011) MR imaging of multiple sclerosis. Radiology 259:659–681
    Fodero-Tavoletti MT, Rowe CC, Maclean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL (2009) Characterization of PIB binding to white matter in Alzheimer disease and other dementias. J Nucl Med 50:198–204
    Fukumitsu N, Ishii K, Kimura Y, Oda K, Hashimoto M, Suzuki M, Ishiwata K (2008) Adenosine A (1) receptors using 8-dicyclopropylmethyl-1-[(11) C] methyl-3-propylxanthine PET in Alzheimer’s disease. Ann Nucl Med 22:841–7
    Gajofatto A, Bongianni M, Zanusso G, Bianchi MR, Turatti M, Benedetti MD, Monaco S (2013). Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. Acta Neurol Scand; Apr 1. doi: 10.1111/ane.12123. [Epub ahead of print]
    Gomez O, Arevalo-Martin A, Garcia-Ovejero D, Ortega-Gutierrez S, Cisneros JA, Almazan G, Sanchez-Rodrigues MS, Molina-Holgado F, Molina-Holgado E (2010) The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 58:1913–1927
    Greene Y, Tariot P, Wishart H, Cox C, Holt CJ, Schwid S et al (2000) A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 20:350–356
    Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter. Trial Ann Neurol 66(4):460–471
    Honce JM (2013) Gray matter pathology in MS: neuroimaging and clinical correlations. Multi Scler Int 2013:627870
    Ishiwata K, Kimura Y, de Vries EFJ, Elsinga PH (2007) PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. Cent Nerv Syst Agents Med Chem 7:57–77
    Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, Power C (2001) Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 49:650–8
    Jonson SD, Welch MJ (1999) Synthesis, biological evaluation, and baboon PET imaging of the potential adrenal imaging agent cholesteryl-p-[18 F] fluorobenzoate. Nucl Med Biol 26:131–138
    Káradóttir R, Attwell D (2007) Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 145:1426–1438
    Khayum MAK, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, Doorduin J (2014). In Vivo Imaging of Brain Estrogen Receptors in Rats: A 16α-18 F-Fluoro-17β-Estradiol PET Study. J Nucl Med. [Epub ahead of print].
    Kimura Y, Ishii K, Fukumitsu N, Oda K, Sasaki T, Kawamura K, Ishiwata K (2004) Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C] 8-dicyclopropylmethyl-1-methyl-3-propylxanthine. Nucl Med Biol 31:975–81
    Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, Zoghbi SS, Hyde T, Kleinman JE, Pike VW, McMahon FJ, Innis RB (2013) A genetic polymorphism for translocator protein 18kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 33:53–8
    Krupp L, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579–1585
    Kumar S, Patel R, Moore S, Crawford DK, Suwanna N, Mangiardi M, Tiwari-Wooodruff SK (2013) Estrogen receptor â ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model for multiple sclerosis. Neurobiol Dis 56:131–144
    Lassman H (2013) Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. doi: 10.1016/j.jns.2013.05.010
    Lassman H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585:3715–3723
    Laube M, Kniess T, Pietzsch J (2013) Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity–a critical update. Molecules 18(6):6311–6355
    Luessi F, Siffrin V, Zipp F (2012) Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Ver Neurother 12:1061–1076
    Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J et al (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492–497
    Matthews PM (2009) Brain imaging of multiple sclerosis: the next 10 years. Neuroimag Clin N Am 19:101–112
    Mattner F, Staykova M, Berghofer P, Wong HJ, Fordham S, Callaghan P, Jackson T, Pham T, Gregoire MC, Zahra D, Rahardjo G, Linares D, Katsifis A (2013) Central nervous system expression and PET imaging of the translocator protein in relapsing-remitting experimental autoimmune encephalomyelitis. J Nucl Med 54:291–298
    McCarthy TJ, Sheriff AU, Graneto MJ, Talley JJ, Welch MJ (2002) Radiosynthesis, in vitro validation, and in vivo evaluation of 18 F-labeled COX-1 and COX-2 inhibitors. J Nucl Med 43(1):117–124
    McDonald WI, Ron MA (1999) Multiple sclerosis: the disease and its manifestations. Philos Trans R Soc Lond B Biol Sci 354:1615–22
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van der Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the Intenational Panel on the Diagnosis of Multiple sclerosis. Ann Neurol 50:121–127
    McGinnity CO, Hammers A, Barros DAR, Luthra SK, Jones PA, Trigg W et al (2014) Initial Evaluation of 18 F-GE-179, a putative PET tracer for activated N-Methyl d-Aspartate receptors. J Nucl Med 55:423–430
    Minghetti L (2004) Cycloooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901–910.
    Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvemente of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22:9742–9753
    Moresco RM, Casati R, Lucignani G, Carpinelli A, Schmidt K, Todde S, Colombo F, Fazio F (1995) Systemic and cerebral kinetics of 16 alpha [18 F] fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab 15:301–311
    Nelissen K, Mulder M, Smets I, Timmermans S, Smeets K, Ameloot M, Hendriks JJ (2012) Liver X receptors regulate cholesterol homeostasis in oligodendrocytes. J Neurosci Res 90:60–71
    Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, Harberts E, Fujimura Y, Richert ND, Ohayon J, Pike VW, Zhang Y, Zoghbi SS, Innis RB, Jacobson S (2011) Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuro Phar 6:354–61
    Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF (2009) Adenosine A (2A) receptor mediates microglial process retraction. Nat Neurosci 12:872–878
    Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O’Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L (2007) Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448:474–479
    Padma MV, Adineh M, Pugar K, Mukherjee J, Satter M, Shi B, Dunigan K, Bidwell K, Ezzeddine B, Mantil J (2005) Functional imaging of a large demyelinating lesion. J Clin Neurosci 12(2):176–8
    Paulesu E, Perani D, Fazio F, Comi G, Pozzilli C, Martinelli V, Filippi M, Bettinardi V, Sirabian G, Passafiume D, Anzini A, Lenzi GL, Canal N, Fieschi C (1996) Functional basis of memory impairment in multiple sclerosis: a [18 F] FDG PET study. Neuroimage 4:87–96
    Pettersson K, Gustafsson JA (2001) Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 63:165–92
    Pittock SJ, Lucchinetti CF (2007) The pathology of MS. New insights and potential clinical applications. Neurologist 13:45–56
    Politis M, Gianetti P, Su P, Turkheiner F, Keihaninejad S, Wu K, Waldman A, Malik O, Matthews PM, Reynolds R, Nicholas R, Piccini P (2012) Increased PK11195 PET binding in the córtex with MS correlates with disability. Neurology 79:523–530
    Popescu BFG, Lucchinetti CF (2012) Pathology of demeylinating diseases. Annu Rev Pathol Mech Dis 7:185–217
    Prabhakaran J, Underwood MD, Parsey RV, Arango V, Majo VJ, Simpson NR, Van Heertum R, Mann JJ, Kumar JS (2007) Synthesis and in vivo evaluation of [18 F]-4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide as a PET imaging probe for COX-2 expression Bioorg Med Chem;15 (4):1802–1807.
    Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiate soon after menopause. Am J Epidemiol 170:12–23
    Ratchford JN, Endres CJ, Hammoud DA, Pomper MG, Shiee N, McGready J, Pham DL, Calabresi PA (2012) Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol 259:1199–1205
    Ribeiro R, Yu F, Wen J, Vana A, Zhang Y (2013). Therapeutic potential of a novel cannabinoid agent CB52 in the mouse modelof experimental encephalomyelitis. Neuroscience. [Epub ahead of print].
    Rissanen E, Virta JR, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, Airas (2013). Adenosine A2A receptors in secondary progressive multiple sclerosis: a [11C] TMSX brain PET study. J Cereb Blood Flow Metab. [Epub ahead of print].
    Rodgers JM, Robinson AP, Miller SD (2013) Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med 16:53–63
    Rojas S, Martín A, Pareto D, Herance JR, Abad S, Ruíz A, Flotats N, Gispert JD, Llop J, Gómez-Vallejo V, Planas AM (2011) Positron emission tomography with 11C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2 h-transient focal ischemia. Neuroscience 182:208–216
    Rom S, Persidsky Y (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol 8:608–20
    Rommer P, Dudesek A, Stüve O, Zettl U (2013) Monoclonal Antibodies in Treatment of Multiple Sclerosis. Clin Exp Immunol. doi: 10.1111/cei.12197
    Rose JW, Foley J, Carlson N (2008) Monoclonal antibody treatments for multiple sclerosis. Curr Neurol Neurosci Rep 8(5):419–426
    Rossi S, Studer V, Motta C, De Chiara V, Barbieri F, Bernardi G, Centonze D (2012) Inflammation inhibits GABA transmission in multiple sclerosis. Mult Scler 18:1633–1635
    Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA (2005) High cholesterol level isessential for myelin membrane growth. Nat Neurosci 8:468–475
    Sahraian MA, Eshaghi A (2010) Role of MRI in diagnosis and treatment of multiple sclerosis. Clin Neurol Neurosurg 112:609–615
    Sand IBK, Lublin FD (2013) Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn) 19:922–943
    Schiepers C, Van Hecke P, Vandenberghe R, Van Oostende S, Dupont P, Demaerel P, Bormans G, Carton H (1997) Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 3:8–17
    Shukuri M, Takashima-Hirano M, Tokuda K, Takashima T, Matsumura K, Inoue O, Doi H, Suzuki M, Watanabe Y, Onoe H (2011) In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl Ester. J Nucl Med 52(7):1094–1101
    Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52:421–428
    Sobrio F, Gilbert G, Perrio C, Barré L, Debruyne D (2010) PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Rev Med Chem 10:870–86
    Solbrig MV, Fan Y, Hermanowicz N, Morgese MG, Giuffrida A (2010) A synthetic cannabinoid agonist promotes oligodendrogliogenisis during viral encephalitis in rats. Exp Neurol 226:231–241
    Spence RD, Hamby ME, Umeda E, Itoh N, Du S, Wisdom AJ, Cao Y, Bondar G, Lam J, Ao Y, Sandoval F, Suriany S, Sofroniew MV, Voskuhl RR (2011) Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci 108:8867–8872
    Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, Wu C, Feinstein D, Huang GF, Semah F, Mathis CA, Klunk W, Gould RM, Lubetzki C, Zalc B (2006) Imaging of CNS myelin by positron emission tomography. PNAS 103:9304–9309
    Stankoff B, Freeman L, Aigrot MS, Chardain A, Dollé F, Willinas A, Galanaud D, Armand L, Lehericy S, Lubetzki C, Zalc B, Botlaender M (2011) Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [Methyl-11C]-2-(40-Methylaminophenyl)-6-Hydroxybenzothiazole. Ann Neurol 69:673–680
    Stuart M, Bergstrom L (2011) Pregnancy and multiple sclerosis. J Midwifery Womens healthy 56:41–47
    Stys PK, Lipton SA (2007) White matter NMDA receptors: an unexpected new therapeutic target? Pharmacol Scie 28:561–566
    Stys PK, Zamponi GW, van Minnen J, Geurts JJG (2012) Will the real multiple sclerosis please stand up? Nat Rev Neurosci 13:507–514
    Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S (1998) Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med 12:89–94
    Takano A, Piehl F, Hillert J, Varrone A, Nag S, Gulyás B, Stenkrona P, Villemagne VL, Rowe CC, Macdonell R, Tawil NA, Kucinski T, Zimmermann T, Schultze-Mosgau M, Thiele A, Hoffmann A, Halldin C (2013) In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18 F] FEDAA1106. EJNMMI Res 3:30
    Tameh AA, Clarner T, Beyer C, Atlasi MA, Hassanzadeh G, Naderian H (2013). Regional regulation of glutamate signaling during cuprizone-induced demeylination in the brain. Annals of Anatomy. [Epub ahead of print].
    Tsao J, Heilman K (2005) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 64:1823
    Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C (2004) A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 24:1521–1529
    Tsutsui S, Vergote D, Shariat N, Warren K, Ferguson SS, Power C (2008). Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells FASEB J; 22:786–796.
    Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ (2011) Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res 4(10):1536–1545
    van den Hoff J (2005) Principles of quantitative positron emission tomography. Amino Acids 29:341–353
    Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G (2008) Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18) F] MK-9470 PET. Neuroimage 39(4):1533–1541
    van Noort JM, Bsibsi M, Gerritsen WH, van der Valk P, Bajramovic JJ, Steinman L, Amor S (2010) Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 69:694–703
    Vas A, Shchukin Y, Karrenbauer VD, Cselényi Z, Kostulas K, Hillert J, Savic I, Takano A, Halldin C, Gulyás B (2008) Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C] vinpocetine and [11C] PK11195 in patients. J Neurol Sci 264:9–17
    Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, Dierckx RA, Korf J, De Reuck JL (2005) Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 11:127–34
    Vincenzi F, Corciulo C, Targa M, Merighi S, Gessi S, Cassetta I, Gentile M, Granieri E, Borea PA, Varani K (2013) Multiple sclerosis lymphocytes upregulated A2A adenosine receptors that are anti-inflammatory when stimulated. Eur J Immunol 43:2206–2216
    Virta JR, Laatu S, Parkkola R, Oikonen V, Rinne JO, Ruutiainen J (2011) Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Mult Scler 17:931–938
    Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP (1997) PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 50:345–53
    Wadsak W, Mitterhauser M (2010) Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 73:461–469
    Wang Y, Wu C, Caprariello AV, Somoza E, Zhu W, Wang C, Miller RH (2009) In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosc 29:14663–14669
    Wisdom AJ, Cao Y, Itoh N, Spence RD, Voskuhl RR (2013) Estrogen receptor β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. J Neurosci Res 91:901–908
    Wu C, Tian D, Feng Y, Polak P, Wei J, Sharp A, Stankoff B, Lubetzki C, Zalc B, Mufson EJ, Gould RM, Feinstein DL, Wang Y (2006) A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem 54:997–1004
    Wu C, Wang C, Popescu DC, Zhu W, Somoza EA, Zhu J, Condie AG, Flask CA, Miller RH, Macklin W, Wang Y (2010) A novel PET marker for in vivo quantification of myelination. Bioorg Med Chem 18:8592–8599
    Wu C, Li F, Niu G, Chen X (2013a) PET imaging of inflammation biomarkers. Theranostics 3:448–466
    Wu C, Zhu J, Baeslak J, Zaremba A, Hecker J, Kraso J, Matthews PM, Miller RH, Wang Y (2013b) Longitudinal PET imaging for monitoring myelin repair in the spinal cord. Ann Neurol 74:688–98
    Xie L, Yamasaki T, Ichimaru N, Yui J, Kawamura K, Kumata K, Hatori A, Nonomura N, Zhang MR, Li XK, Takahara S (2012) [(11) C] DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model. J Neuro Pharmacol 7:231–42
    Xu P, Li D, Tang X, Bao X, Huang J, Tang Y, Yang Y, Xu H, Fan X (2013). LXR Agonists: New potential therapeutic drug for neurodegenerative diseases. Mol Neurobiol [Epub ahead of print].
    Zajicek JP, Apostu VI (2011) Role of cannabinoids in multiple sclerosis. CNS Drugs 25:187–201
    Zanzonico P (2012) Principles of nuclear medicine imaging: Planar, SPECT, PET, multi-modality, and autoradiography systems. Radiation Reseach 177:349–364
    Zhao Y, Robins E, Turton D, Brady F, Luthra SK, Arstad E (2006) Synthesis and characterization of N-(2-chloro-5-methylthiophenyl)-N0-(3-methylthiophenyl)-N0-[11C] methylguanidine [11C] CNS 5161, a candidate PET tracer for functional imaging of NMDA receptors. J Label Compd Radiopharm 49:163–170